In the most recent trading session, Synopsys (SNPS) closed at $601.55, indicating a -1.33% shift from the previous trading day.

MoneyFlows data shows how Big Money investors are again betting heavily on the stock. Institutional volumes reveal plenty. In ...

Dental caries remains a significant global public health burden, affecting billions worldwide despite preventive measures. While behavioral and ...

There's plenty of reason to be optimistic about Synopsys' future; however, whether it could realistically make you a ...

The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The top-performing stocks tend to have a 95 or better grade as they ...

Scottish first minister John Swinney used Donald Trump’s visit to make new promises over a second independence referendum, ...

Cadence Design Systems (CDNS) tops Q2 expectations, lifts 2025 outlook amid AI-driven demand. Analysts boost price targets; ...

The precedent set by the SNP’s 2011 election victory would break the “logjam” towards a second independence referendum, John ...

Synopsys (SNPS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Medicare Advantage enrollment grew by about 1.3 million beneficiaries, or 4%, over the last year, slowing the program’s explosive growth rate compared to prior years, according to a new analysis.

Researchers evaluated the relative importance of phenotypic and genetic factors in predicting risk for head and neck cancer.

This study reveals how machine learning models uncover new genetic variants linked to Alzheimer’s, advancing predictive ...